Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D.

from Answers from the Lab · host Mayo Clinic Laboratories

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new test measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.(00:32) Can you tell us a little bit about yourself and your background? (01:33) Could you give us a brief overview of this assay? (02:47) Which patients should have this testing, and when should it be performed? (03:48) How would the results be used in patient care?

Episode metadata supplied by the publisher feed · Published Jul 1, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Labile Copper Test Enhances Evaluation for Wilson's Disease: Joshua Bornhorst, Ph.D.

0:00 6:51

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Answers from the Lab?

This episode is 6 minutes long.

When was this Answers from the Lab episode published?

This episode was published on July 1, 2025.

Can I download this Answers from the Lab episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!